Clinical Trial Update: A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial PROCEED is a Phase 1/2 study evaluating PR001 (LY3884961) for peripheral manifestations of Gaucher disease, and the trial is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease
• Gaucher Disease Type

Drugs mentioned

• PR001 (LY3884961) (LY3884961)

Snippet

Sponsor: Prevail Therapeutics | Conditions: Gaucher Disease, Gaucher Disease, Type 1 | Phase 1, Phase 2 | Status: RECRUITING